Home » Topics » BioWorld Science

BioWorld Science
RSS

Actinium studies Actimab-A with venetoclax for AML in new phase I/II trial

Feb. 6, 2019

Boehringer and Hydra Biosciences patent TRPC5 antagonists

Feb. 6, 2019

Genentech and NewLink Genetics identify TDO inhibitors

Feb. 6, 2019

Aivita reports new findings on mechanism of action for Root of Cancer technology

Feb. 6, 2019

FDA agrees Cytogel may proceed with phase Ia/IIa study of CYT-1010

Feb. 6, 2019

Galapagos and Calchan patent MAP3K5 inhibitors

Feb. 6, 2019

Sichuan Kelun-Biotech Biopharmaceutical divulges IDO1 inhibitors

Feb. 6, 2019

EHMT1/2 targeting restores NMDAR function and social behavior in mouse model of autism

Feb. 6, 2019

Valerion Therapeutics presents clinical data on VAL-1221 for Pompe disease

Feb. 6, 2019

VIB-9600 demonstrates promising activity and safety in preclinical models of autoimmune disease

Feb. 6, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...